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Abstract: The anticonvulsant topiramate not only decreases ethanol con-
sumption in alcohol dependence (AD) but also may produce several ad-
verse events including cognitive impairment. Zonisamide is a structurally
related anticonvulsant that is a promising agent for the treatment of AD
and may have greater tolerability than topiramate. This study evaluated
the effects of zonisamide (400 mg/d) on alcohol consumption and its neu-
rotoxic effects in subjects with AD. A double-blind placebo-controlled
clinical trial was conducted using 2 comparator anticonvulsant drugs,
topiramate (300 mg/d) and levetiracetam (2000 mg/d), which does not im-
pair cognition. Study medications were administered for 14 weeks, includ-
ing a 2-week taper period. Medication adherence was facilitated using
Brief Behavioral Compliance Enhancement Treatment. The neurotoxicity
of the study drugs was assessed using neuropsychological tests and the
AB-Neurotoxicity Scale. Compared with placebo, both zonisamide and
topiramate produced significant reductions in the drinks consumed per
day, percent days drinking, and percent days heavy drinking. Only the per-
cent days heavy drinking was significantly decreased in the levetiracetam
group. The topiramate cell was the only group that had a significant in-
creaseonthementalslowingsubscaleoftheNeurotoxicityScalecompared
with placebo at study weeks 11 and 12. Topiramate and zonisamide both
producedmodestreductionsinverbalfluency andworking memory.These
findingsindicatethatzonisamidemayhaveefficacyinthetreatmentofAD,
witheffectsizessimilartotopiramate.Bothofthesedrugsproducedsimilar
patterns of cognitive impairment, although only the topiramate group re-
ported significant increases in mental slowing.
Key Words: anticonvulsants, alcohol dependence, cognition
(J Clin Psychopharmacol 2015;35: 34–42)
T
he results of several clinical trials, including 1 multisite study,
indicate that the broad-spectrum, sulfamate-substituted anti-
convulsanttopiramatehasatherapeuticeffectsizeinthemoderate
range for the treatment of alcohol use disorders (AUDs).
1–3 Some
of the most common problematic adverse effects associated with
topiramate administration involve the impairment of cognition
thatmayincludeimpairedverbalfluencyandworkingmemory.
4–6
There is research that suggests that the cognitive adverse effects
that occur with topiramate treatment of AUDS are similar tothose
reported for the treatment of epilepsy, migraine headaches, and
obesity.
5,7 Cognitive impairment induced by topiramate is a com-
mon reason for study dropout and drug discontinuation in clinical
settings.
5 In addition to the effects on cognition, topiramate ad-
ministration also produces a range of other adverse effects, the
most serious of which is metabolic acidosis, resulting from the in-
hibition of carbonic anhydrase.
8
Several sulfamide and sulfonamide compounds have been
identified,whichsharesomeofthestructuralfeaturesoftopiramate
and which have been shown to have actions as broad-spectrum an-
ticonvulsants in animal models of seizure disorders.
9–12 Of these
compounds, only zonisamide is currently approved in the United
States as a medication for use as a broad-spectrum anticonvul-
sant.
13 This drug shares other therapeutic actions with topiramate,
namely, antimigraine effects
14,15 and the facilitation of weight
loss.16 There is also evidence that zonisamide administration may
help to promote reduced alcohol consumption. Ethanol intake
has been found to be lowered by the administration of zonisamide
to either mice or rats in limited access models of drinking.
17 In
humans, the administration of zonisamide decreased ethanol self-
administration in a laboratory setting.
18 Ethanol consumption was
markedly reduced by the administration of zonisamide in both
open-label
19,20 and placebo-controlled clinical trials.
21
Zonisamide, like topiramate, is a carbonic anhydrase inhi-
bitor, but reports in patients with seizure suggest that it has a
lower incidence of both paresthesias (2.5%–11.5% vs ≥22% for
topiramate)
22–25 andmetabolicacidosis.
8Withregardtothelatter,
in a study conducted by Mirza et al,
8 7% of patients treated with
zonisamide had low serum bicarbonate levels, an indicator of ac-
idosis, whereas 29% of individuals receiving topiramate had low
levels of this ion.
Theeffectsofzonisamideoncognitionhavenotbeenstudied
as extensively as have those associated with topiramate. In pa-
tients with seizure, after 1 year of monotherapy with zonisamide,
participants had a significant decline from baseline performance
onmeasuresofverbalfluencyandattention.
26 A pilot studyof pa-
tients with seizure showed impaired performance on the Wechsler
Memory Scale and delayed recall tasks for logical memory and
verbal paired associates.
27 Caution must be exercised in inter-
preting extant studies because some diseases, such as epilepsy, are
associated with greater adverse effects than in obese patients or
patients with AUDS. Subjects with AUDS have reported cognitive
problemswhenreceivingzonisamide.
21Inpreliminaryinvestigative
trials conducted in our clinic, we found that in alcohol-dependent
subjects, the cognitive impairing effects of zonisamide were less se-
vere compared with those resulting from topiramate administra-
tion.
19,28 Formal neuropsychological testing, however, has not
been used to evaluate the effects of zonisamide on individuals with
AUDS in placebo-controlled clinical trials.
The objectives of the present study were to evaluate the effects
of zonisamide administration on ethanol intake and on cognitive
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those meeting Diagnostic Statistical Manual Fourth Edition criteria
for alcohol dependence (AD). Cognitive functioning was assessed
using a battery of neuropsychological tests that measured several
aspects of cognitive functioning, including working memory, lan-
guage function, executive function, as well as visual processing
and psychomotor performance. The A-B Neurotoxicity Scale was
administered in the present study to obtain subjects' reports
concerning their experiences of the neurotoxic actions of anticon-
vulsants. The effects of zonisamide were compared with those of
placebo. Topiramate was also administered to a separate group of
subjects as a positive control. The anticonvulsant levetiracetam
was used as an additional comparator agent. Levetiracetam admin-
istration seems to produce few adverse effects on cognition.
29,30
This drug had shown initial promise as a medication for the treat-
ment of AD,
31 but its use for this purpose has not since been sup-
ported by findings in recent studies.32,33
MATERIALS AND METHODS
Subjects
Eighty-fiveparticipants(37women)aged21to65yearswho
met Diagnostic Statistical Manual Fourth Edition criteria for AD
were admitted into this study. Characteristics of the subjects are
provided in Table 1. Eligibility criteria specified that during the
90-day period preceding screening, men drank 35 or more stan-
darddrinks perweek,whereaswomenconsumed28ormorestan-
dard drinks per week during at least a 4-week-long consecutive
period. Subjects had to have had a score of greater than 8 on the
Alcohol Use Disorder Identification Test
34 and were required to
express a desire to stop drinking or reduce their intake of alcohol.
Female subjects were required to have been using appropriate
birth control procedures before randomization and during the pe-
riod in which study medications were being administered or to be
sterile or to have entered menopause. Pregnant women were ex-
cluded from the study.
Exclusioncriteriafor thisstudyincludeddependenceonsub-
stances other than alcohol, nicotine, or caffeine; a score of 10 or
greater on the Clinical Institute Withdrawal Assessment for Alcohol-
Revised
35 scale during screening; current treatment with acamprosate,
disulfiram, or naltrexone; or the use of any of these drugs less than
2 weeks before randomization. Additional exclusion criteria were
current treatment with sedative hypnotics, opioids (ie, required
chronicopioidstreatment),psychomotorstimulants,orantipsychotic,
antimanic, or anticonvulsant medications.
Allsubjects providedwritteninformed consent, whennot in-
toxicated (ie, blood alcohol concentration, 0.00%), before entry
into the study. This study was undertaken with the approval of the
Boston University Medical Center's Institutional Review Board.
Study Design and Procedures
This placebo-controlled study followed a double-blind, par-
allel group design. An adaptive randomization procedure was
followed in this study with sex and heavy drinking (10 drinks
perdayformenand8drinksperdayforwomen)forallpreviously
randomized subjects used as variable levels. Subjects were ran-
domized into one of the following 4 treatment groups: (1) leveti-
racetam, (2) placebo, (3) topiramate, or (4) zonisamide.
The flow diagram for this study can be found in Sup-
plemental Figure 1 (in Supplemental Digital Content 1,
http://links.lww.com/JCP/A256). Subjects were recruited by adver-
tisements placed on the radio or in newspapers. A telephone inter-
view was used to identify subjects who were qualified to undergo
further screening. Subjects were evaluated during screening ses-
sions to determine whether they met criteria for study admission.
Those meeting the appropriate criteria were randomized to 1 of the
4treatmentgroups.Subjectscouldhavebloodalcoholconcentration
no greater than 0.02% to be allowed to participate in any of the
postscreeningsessions.Thestudyplancalledfor randomizedsub-
jects tovisit thecliniconaweeklybasisfor15consecutiveweeks.
Before the administration of the first dose of study medication,
baseline assessments were obtained. Subjects received medica-
tionsfor14weeks. Thisincluded a 7-weekperiodofgradual dose
increases, 5 weeks of treatment at the target maintenance dose
levels, followed by a 2-week period for tapering of medications
(see study medication dosing schedule in Supplemental Table 1,
in Supplemental Digital Content 2, http://links.lww.com/JCP/A257).
Target maintenance doses were 2000 mg/d for levetiracetam, 300 mg/d
for topiramate, and 400 mg/d for zonisamide. Target maintenance
doses were selected based on the results from previous clinical trials
of the efficacy of levetiracetam,
31 topiramate,
2 and zonisamide
19 in
alcohol-dependent subjects. In addition to receiving study medi-
cation, everysubjectattendeda 15-minuteBrief Behavioral Com-
pliance Enhancement Treatment
36 session during every session
attended between study weeks 1 and 14. The Brief Behavioral
Compliance Enhancement Treatment is a psychosocial adherence
enhancement procedure that emphasizes that medication adherence
is important in the reduction of participants' drinking behavior.
The 4 study medicationswere prepared, stored, and dispensed
bytheBostonMedicalCenter'sInvestigationalDrugService.These
medications were dispensed in identically appearing dark blue cap-
sules. If possible,subjects received the same number of capsules for
each corresponding dayduring the treatmentperiod.The study psy-
chiatrist was permitted to slow the rate at which medication doses
TABLE 1. Subject Description
Group Levetiracetam Topiramate Zonisamide Placebo
N2 1 2 1 1 9 2 4
Age, y 47.5 (10.5) 46.8 (10.5) 47.0 (10.0) 46.8 (7.3)
Female 9 (42.8) 9 (42.9) 8 (42.1) 11 (45.8)
African American 0 (0) 2 (9.5) 1 (5.3) 2 (8.3)
Asian 1 (4.8) 1 (4.8) 0 (0) 1 (4.2)
W h i t e 2 0( 9 5 . 2 ) 1 8( 8 5 . 7 ) 1 8( 9 4 . 7 ) 2 1( 8 7 . 5 )
Education, y 15.2 (2.4) 15.4 (1.9) 15.6 (2.5) 15.3 (2.7)
Full-Scale Wechsler Abbreviated Scale of Intelligence 113.3 (11.6) 113.6 (12.6) 115.3 (8.9) 110.7 (14.0)
AUDIT 23.1 (5.2) 24.6 (7.7) 22.1 (5.9) 23.7 (4.7)
Mean (SD) or n (%) are presented.
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ministered if subjects were unable to tolerate their medications at
any point in the treatment period.
Subjects' self-reports concerning the amount of ethanol they
consumedwerecollectedusingtheTime-LineFollowbackmethods37
throughout the study. γ-glutamyl transpeptidase (GGT) was mea-
sured in blood at screening and study weeks 4, 8, 10, 12, and 15,
as a biomarker of alcohol consumption.
38 Symptoms of with-
drawal were measured during screening and in each subsequent
encounter using the Clinical Institute Withdrawal Assessment for
Alcohol-Revised scale.
35 Blood alcohol concentrations, as mea-
sured using a Breathalyzer, and vital signs were collected during
each session. Alcohol craving was assessed using the 14-item Ob-
sessive Compulsive Drinking Scale (OCDS), a reliable self-rating
instrument that measures cognitive aspects of alcohol craving.39
Depression was evaluated with the Montgomery Asberg Depres-
sion Scale (MADRS),
40 whereas anxiety levels were determined
usingtheHamiltonAnxiety(HAM-A)scale.
41TheHAM-Ascale,
MADRS, and OCDS were administered in study weeks 1, 4, 6, 8,
10, 12, and 15. Latency to sleep onset and hours of sleep per night
were assessed using the Sleep Scale for Medical Outcomes
(MOS).
42 The A-B Neurotoxicity Scale
43 was used to obtain sub-
jects' rating of their experience of adverse effects related to
anticonvulsant-induced neurotoxicity. This scale and the MOS
were administered on study weeks 1, 4, 8, 12, and 15.
Neuropsychological testswere administered on study week 1,
before the start of drug administration, and study week 12, at the
end of maintenance therapy, to evaluate cognitive functioning at
baselineandinthelastweekofmaintenancetherapy.TheWechsler
Abbreviated Scale of Intelligence was used to determine full-scale
intelligence quotients.
44 Working memory was assessed using the
Spatial and Digit Span tests from the Wechsler Memory Scales-
ThirdEdition (WMS-III).
45 The Rey Audio VisualLearningTest
46
wasadministeredto examineverbalmemory,whereasvisualmem-
ory was evaluated through the use of the Rey Complex Figure
Memory and Recognition Tests.
47 Verbal fluency was assessed
using the Controlled Word Association Test (COWAT).
48 The
Stroop Color-Word Test,
49 Trail Making Tests
50 and Wisconsin
CardSortTest
51wereadministeredtoevaluateexecutivefunction.
Psychomotorfunction,attention,andvisual-motor processingwere
assessed using part A of the Trail Making Test, the Symbol Digit
Modalities Test,
52 and the Grooved Pegboard Test.
53
Statistical Analysis
Unless otherwise indicated, data are presented as mean ± SE
values. Baseline group data for drinking and other measures were
compared using 1-way analysis of variance, except for compar-
isons of proportional data, for which w
2 tests were used. An
intent-to-treat approach was used to analyze all repeated outcome
measuresexceptthosefortheneuropsychologicaltesting.Datafor
the neuropsychological tests were available for only study weeks
1 and 12 and were analyzed only for subjects for whom week 12
datawereavailable.Toassesstheeffectsofsubjectdropout,anad-
ditionalsensitivityanalysiswasconductedondataforthedrinking
measures using a last observation carried forward approach. This
approach entailed last observation carried forward values being
usedtoreplacedatamissingafter thelastobservationinthemixed
models analyses described later. The same approach was used to
analyzeresultsfor the COWAT, whichwere usedas representative
samples of data for the neuropsychological tests. The data from
the COWAT were further analyzed using an intent-to-treat ap-
proach to see if the results were comparable with those obtained
for the completers' data set.
Drinking measures derived from the Time-Line Followback
dataincludedthepercentdaysdrinking,thenumberofdrinkscon-
sumed per day, and the percent days heavy drinking. Heavy drink-
ing was defined as 4 or more drinks per day for women and 5 or
more drinks per day for men. Alcohol consumption measures were
analyzed using repeated-measures mixed models analysis using
SAS PROC MIXED (version 9.3; SAS Institute, Cary, NC) with
baseline values for these measures used as covariates. Compari-
sonswere made for dataobtained for the 12-week treatment period
for all 4 groups. An additional analysis was conducted on paired
comparisons between values for the placebo group and each of
the active medication groups. For the paired comparisons, the
SLICE option available in PROC MIXED was used to determine
differences between pairs of groups for study weeks 10, 11, and
12. The SLICE option offers a means for performing a partitioned
analysis of the least square means for an interaction. Also known
as the analysis of simple effects, the SLICE analysis can provide
results for the paired comparisons of least square means for any
given unit of time, for example, treatment week. During weeks
10, 11, and 12, drug blood concentrations should be at steady-
state levels. This was based on the assumption that zonisamide,
which has a half-life in the range of 50 to 60 hours,
54 the longest
of any of the study medications, would attain steady-state levels
at 2 weeks after the initiation of administration of the maintenance
dose in week 8.
Data collected for the A-B Neurotoxicity Scales, HAM-A
scale, MADRS, OCDS, and Sleep-MOS, were also analyzed with
repeated-measures mixed models analysis, with baseline values for
these measures used as covariates. A similar approach was used to
analyze GGT data, which were first transformed to natural loga-
rithm values to reduce excessive skewness and kurtosis detected
in the initial examination of the GGT values. The mental slowing
and memory subscales of the Neurotoxicity Scales were also ana-
lyzed because they assess aspects of cognition that are likely to be
negatively influenced by topiramate. Because subjects were not
always able to attend sessions as originally scheduled, 2 weeks
long rather than 1 week long, time bins were used to classify the
time of assessment for measures that were collected on a less-
than-weeklybasisinanefforttoprovideamoreaccuraterepresen-
tation of the times at which these data were collected. That is to
say,the12-weektreatmentperiodwasbrokenintosix2-weekseg-
ments, with, for example, assessments being obtained for weeks
11 and 12 being placed into the segment 6 assessment period. If
a particular time segment contained 2 values, the mean of these
values was used in the analysis.
α levels of less than 0.05 were considered to be significant.
An exception was when a value of less than 0.017, based on a
Bonferroni correction, was regarded as being significant when
3 paired comparisons between the placebo and each of the active
medication groups were made. In an effort to control for multiple
comparisons, a second exceptionwasalso made for the neuropsy-
chological test results. For these tests, differences from placebo
values were considered to be significant only when the α value
was less than 0.01 for the group-by-time interaction for compari-
sons with placebo. A P value of 0.05 was taken to be significant
forSLICEeffectsanalysisofpairedcomparisons betweenthepla-
cebo group and other individual active medication groups. The
results of the SLICE analysis, consequently, are best considered
as only an exploratory examination of the direction differences
between these paired groups during the treatment period.
RESULTS
Demographic data for subjects are presented in Table 1,
along with the findings for the AUDIT, WAIS Full-Scale IQ
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not significant with respect to any of these variables. The per-
centageofsubjectsineachtreatmentgroupwhowereabletocom-
plete assessments for week 12 of the study were 81% for the
levetiracetam group, 79% for the placebo group, 71% for the
topiramate group, and 79% for the zonisamide group (see
Supplemental Figure 1, in Supplemental Digital Content 1,
http://links.lww.com/JCP/A256 for the number of subjects dur-
ing each phase of the study). Based on pill count results, the
mean ± SE percentage of prescribed drugs used by subjects
while in the treatment period was 93.1% ± 4.7% for the leveti-
racetam group, 87.6% ± 5.7% for the placebo group, 95.4% ±
2.5% for the topiramate group, and 90.5% ± 4.4% for the
zonisamide group. These percentages did not differ signifi-
cantly among these groups.
Data obtained at baseline and during the 12-week treatment
period for the number of drinks consumed per day and the percent
days heavy drinking are presented in Figure 1. Findings for the
weekly percent days drinking appear in Figure 2. Nogroup differ-
enceswerefoundforanyofthe3measuresofdrinkingobtainedat
baseline. Treatment effects were significant for the percent days
drinking (F3,81.2 = 6.7, P = 0.0005), the number of drinks con-
sumed per day (F3,81.4 = 4.8, P = 0.004), and the percent days
heavy drinking (F3,84.4 =5 . 5 ,P = 0.002). The group-by-time
interactions were not significant for any of these measures. For
the pairwise comparisons between the placebo and topiramate
groups, significant treatment effects were seen for weekly percent
days drinking (F1,41.6 =1 9 . 8 ,P < 0.0001), percent days heavy
drinking (F1,41.8 =1 9 . 4 ;P < 0.0001), and drinks consumed per
day (F1,41 =1 3 . 5 ,P = 0.0007). SLICE effects showed that values
for all 3 drinking measures were significantly lower in the
topiramate group as compared with the placebo group for weeks
10 to 12. For the placebo and zonisamide groups comparisons,
treatment effects were significant for the percent days drinking
(F1,42.8 =8 . 4 ,P = 0.006), percent days heavy drinking (F1,43 =
10.8, P = 0.002), and drinks consumed per day (F1,40.8 = 7.5,
P = 0.009) measures. Values for the percent days drinking and
percent days heavy drinking were significantly less for the
zonisamide group than for the placebo for weeks 10 to 12. For
the number of drinks consumed per day, the values for the
zonisamide group were only significantly lower than those for
the placebo group for week 11. When the levetiracetam and pla-
cebo groups were compared, significant treatment effects were
found only for the percent days heavy drinking (F1,43.2 = 7.4,
P = 0.009), with values for the levetiracetam group being signifi-
cantlylessthanthoseobtainedfortheplacebogroupduringweeks
10 to 12. Drinking measure values that were found to be signifi-
cantfor pairedcomparisonsintheintent-to-treatdatasetwerealso
found to be significant in the sensitivity analysis, with the excep-
tion of those for the percent days drinking for the comparison of
the zonisamide and placebo groups. The treatment effect P value
for this comparison increased from 0.006 in the intent-to-treat
analysis to 0.0176 in the sensitivity analysis.
Least square means values obtained for the follow-up evalu-
ation session were significantly lower for the topiramate group as
comparedwiththeplacebogroupfor themeandrinksconsumedper
day (P = 0.02) and the mean percent days drinking (P =0 . 0 2 ) .
This comparison was not significant for the mean value of the
percent heavy drinking days. None of the values for the posttreat-
ment evaluation were found to be significant when values for the
FIGURE 1. Ethanol consumption for subjects in the levetiracetam
(LEV), placebo (PLC), topiramate (TOP), and zonisamide (ZON)
groups. Mean ± SE weekly values are presented for drinks per day
(top) and percent days heavy drinking (bottom) obtained during
the prescreening (week 0), titration (weeks 1–7), and maintenance
phases of the study (weeks 8–12).
FIGURE 2. Mean weekly values for percent days drinking for
subjects in the levetiracetam (LEV), placebo (PLC), topiramate
(TOP), and zonisamide (ZON) groups. These values are presented
for the percent days drinking obtained during the prescreening
(week 0), titration (weeks 1–7), and maintenance phases of the
study (weeks 8–12).
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levetiracetam or zonisamide groups.
The mean GGT blood concentrations obtained at screening
were higher than the upper limit for normal values (ie, 58 U/L)
for all but the zonisamide group. For log-transformed GGT
concentrations obtained at screening and for study weeks 3 to 12,
the group-by-time interaction was found to be significant
(F12,180 =3 . 0 ,P = 0.0009). The pairwise comparison ln GGT
valuesfor thetopiramateandplacebogroups showedasignificant
group-by-time interaction (F4,127 =5 . 0 ,P = 0.0009). Least square
means ln (GGT) values for the topiramate group [(Seg-5 = 3.5
(0.2); Seg 6 = 3.3 (0.2)] were significantly lower than those ob-
tained for the placebo group in the week 9 and 10 [Seg 5 = 3.8
(0.2)] and week11and12segments [Seg 6= 3.8(0.2)].Thetreat-
ment and group-by-time effects were not significant for the com-
parisons of ln (GGT) values for the zonisamide and placebo
values and for levetiracetam and placebo.
Meanvaluesobtainedfor theOCDSduringthetreatmentpe-
riod are shown in Figure 3. Repeated-measures analysis of these
values obtained for total OCDS scores revealed a significant
group-by-time interaction (F15,102 = 1.9, P = 0.032). Only the
pairwise comparison between the topiramate and placebo groups
showed a significant group-by-time interaction (F5,51.9 = 3.6,
P = 0.007) for OCDS values measured during the treatment pe-
riod. Least square means OCDS scores for the topiramate group
weresignificantlylowerthanthoseobtainedfortheplacebogroup
in the week 9 and 10 segment and the week 11 and 12 segment.
Scores for this measure followed a similar trend for both the leve-
tiracetam and zonisamide groups; however, no significant effects
were found for the paired comparisons of values obtained for
these 2 groups with those found for the placebo group. Treatment
effects and group-by-time interactions were not found for any of
thecomparisonsmadefor the HAM-A scalescorewiththeexcep-
tion of the group-by-time effect (F5,76.4 = 3.9, P = 0.003) for the
comparison between the topiramate and placebo groups (Fig. 4).
SLICE effects showed topiramate group HAM-A scale scores to
be significantly higher than placebo group scores for the week
1a n d2s e g m e n t( P = 0.01). None of comparisons obtained for
the MADRS scores were found to be significant.
Mean ± SE total hours of sleep per night determined using
the Sleep-MOS scales at baseline were 7.0 ± 0.3 for the levetirac-
etam group, 6.8 ± 0.3 for the placebo group, 6.9 ± 0.4 for the
topiramate group, and 6.9 ± 0.2 for the zonisamide group. These
baseline values did not differ significantly among the groups.
Analysis of data for the total hours of sleep per night and the la-
tency to the onset of sleep did not reveal any significant differ-
ences among thegroups duringthecourse of thetreatment period.
For pairwise comparisons of topiramate versus placebo data
for A-B Neurotoxicity Scales, the treatment effect (F1,39.2 = 8.0,
P = 0.008) was significant for the mental slowing subscale, with
the effect slices being significant only for the week 11 and 12 seg-
ment [P = 0.005) (see Supplemental Table 2, Supplemental Digital
Content 3, http://links.lww.com/JCP/A258). For the total Neuro-
toxicity Scale scores, the α value for the treatment effect was
0.03, which is not significant after the correction for multiple com-
parisons, with an α value of 0.015 found for the week 11 and
12 segment. For the memory subscale of the Neurotoxicity Scale,
none of the effects examined for the overall analysis were signifi-
cant, but the tests of SLICE effects had an α value of 0.011 for
the week 11 and 12 segment. Taken together, these results suggest
that subjects on the topiramate group experienced greater neuro-
toxicity symptoms in the last 2 weeks of the maintenance phase
of the study. A significant group-by-time interaction was found
for the comparison between the zonisamide and placebo groups
(F3,60.7 =3 . 8 ,P = 0.015) for the Neurotoxicity memory subscale,
with SLICE effects showing a significantly lower value for the
zonisamide than for the placebo group in weeks 3 and 4 (ie, before
the maintenance dose). The group-by-time interaction was also sig-
nificant for pairwise comparisons between the levetiracetam and
FIGURE 3. Mean ± SE total OCDS scores for each treatment
group obtained during the titration and maintenance phases of
the study.
FIGURE 4. Mean ± SE MADRS (top) and HAM-A scale (bottom)
scores for each treatment group obtained during the titration
and maintenance phases of the study.
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subscale (F3,92.3 =3 . 6 ,P = 0.017), with no SLICE effects showing
a significant between-group difference during the treatment period.
The impairment of both verbal and visuospatial working
memory in the topiramate and zonisamide groups was indicated
by significant group-by-time interactions for comparisons between
the placebo group and these medication groups for performance
on the Forward portions of the Spatial and Digit Spans tests, with
decreased scores being obtained for the 2 anticonvulsant groups
whereas slight elevations were seen for scores of the placebo group
(see Supplemental Table 2, in Supplemental Digital Content 3,
http://links.lww.com/JCP/A258). Additional evidence for topiramate-
induced deficits in working memory is indicated by significant
group-by-time interactions for comparisons between the placebo
group and this medication group for both age-adjusted and total
scores of the Spatial Span and Digit Span tests. In addition, a sig-
nificantinteractionwasfoundfor thebackwardportionoftheDigit
Span test for the comparison of the topiramate and placebo, which
is consistentwith an impairmentinverbalworking memoryhaving
been produced by the administration of this anticonvulsant.
TheinteractionforcomparisonsfortotalscoresfortheAudio
Visual Learning Test was significant, for both the topiramate and
zonisamide groups, with reductions occurring in scores in both
groupsascomparedwiththoseobtained for theplacebogroup.These
results indicate that these drugs produced impairment of verbal mem-
ory. A significant group-by-time interaction was also found for the
topiramate-placebo comparison for the total recognition score for
the Rey Complex Figure test, with scores being reduced only for
the topiramate group. This suggests that topiramate may also ad-
versely affect visual memory. Significant group-by-time interac-
tions for comparison with the placebo group on both the Phonetic
and Semantic portions of the COWAT seen for both the topiramate
andzonisamidegroups,withscoresbeingdecreasedineachofthese
anticonvulsant groups, indicate that these 2 medications can impair
verbal fluency. Similar resultswere found for both the intent-to-treat
and sensitivity analyses of data obtained for the COWAT.
Performance on the Trail Making Test Part B was signifi-
cantly impaired for the zonisamide group when compared with
the placebo, with time to complete the trial being elevated in the
zonisamide group. The group-by-time interaction for the Trails
B Test approached significance when results were examined for
the topiramate group (F1,18.1 = 8.0, P = 0.011). These results for
the Trail Making Test are indicative of reductions in executive
functioning, but results obtained for the Stroop Test and Wiscon-
sin Card Sorting Test (WCST) suggest that either topiramate
or zonisamide administration do not negatively influence many
aspects of executive function.
No significant group-by-time interactions for comparisons
between the placebo group and the levetiracetam group were found
for any of the neuropsychological tests that were administered in
this study (see Supplemental Table 3, in Supplemental Digital Con-
tent 4, http://links.lww.com/JCP/A259).
A serious adverseevent involvingasuicideattempt usingthe
study medication occurred in1 subject, whowas in the zonisamide
group. This serious adverse event, however, was rated as being
only remotely related to the use of zonisamide. One subject in the
topiramategroup developed metabolic acidosis. Irritabilityoccurred
in a significantly larger proportion of subjects (24%) who were be-
ing treated with topiramate than the proportion for those being
treatedwithplacebo.Irritabilitywasnotreportedbyanyofthesub-
jects who were treated with zonisamide. Moreover, paresthesias
occurred in 19% of the subjects who received topiramate, whereas
none were found in subjects who were treated with zonisamide.
Unexpectedly, 14% of the subjects in the topiramate group re-
ported problems with erectile dysfunction.
DISCUSSION
The results of the present study demonstrate in subjects with
AD that,compared with a treatment with placebo, the administration
ofeitherzonisamideortopiramatereducedethanolintakeonallof
the3measuresofalcoholconsumptionused,namely,percentdays
drinking per week, drinks consumed per day, and percent days
heavy drinking per week. These findings are consistent with those
of previous clinical trials indicating that zonisamide
21 and to-
piramate
1,2,55–57 decrease alcohol consumption in subjects with
AUDS. Although previous placebo-controlled studies have failed
to show that levetiracetam administration produces a decrease in
alcohol consumption,
32,33 inthe present study, thisanticonvulsant
wasfoundtosignificantlyreducethepercentdaysheavydrinking.
The factors that may account for the disparity in these findings
remain to be determined.
In the present study, GGT levels were significantly lower at
theendofmaintenancephaseforthetopiramateascomparedwith
the placebo group, and there was a significant group-by-time inter-
action for the pairwise comparison for this group, indicating that
topiramate administration lowered GGT blood levels to a greater
extent than did placebo. This finding is consistent with those pre-
viously reported for topiramate treatment of alcohol-dependent
subjects.
1 In so far as GGT levels can be considered to be a bio-
marker of alcohol consumption, they support the self-report data
that topiramate significantly reduced alcohol consumption.
Significant differences were not found in comparisons of
GGTconcentrationsobtained foreither thezonisamide or the leve-
tiracetamgroupswiththoseobtainedfor theplacebogroup.For the
zonisamide group, in the present study, the value of using GGTas
a biomarker for alcohol consumption is limited because mean con-
centrations of this enzyme, in contrast to those obtained for the
other groups, were well within the normal range at screening.
Thepresentstudyseems tobethefirstinvestigationinwhich
the effects of either topiramate or zonisamide on cognitive func-
tion in individuals with AD were assessed using a full battery
of neuropsychological tests. Treatment with either topiramate or
zonisamide was associated with increased difficulty with verbal
fluency and verbalworking memory. In the present study, impair-
ment of visual memory was detected in the topiramate but not the
zonisamide group. Treatment with topiramate did not produce di-
minished executive functioning as assessed using the WCST or
StroopTest.Therewas,however,atrendfor towarddecreasedper-
formance on the Trail Making Test Part B, which may also assess
aspects of executive function.
58 Zonisamide administration did
produce a decrement in the performance on the Trail Making Test
Part B, suggesting a possible negative impact on executive func-
tion. Executive functioning, however, as measured by the WCST
and the interference and color-word portions of the Stroop test
was not impaired by this drug.
Thefindingsfor theA-B NeurotoxicityScalerevealpossible
differences in subjects' self-reports concerning their experience
of the neurotoxic effects of these drugs. Results for the mental
slowing subscale indicated that mental slowing was found to be
worsened only by the administration of topiramate. Moreover,
the SLICE effects analysis showed scores elevated above placebo
group levels only for the topiramate group for both the memory
and total scale scores for the Neurotoxicity Scale in the final
2 weeks of the maintenance therapy phase of the study. These re-
sults suggest that topiramate may have adverse neuropsychologi-
cal effects in subjects with AUDS that are not detected by the
cognitive tests used in the present study.
Incontrasttotreatmentwitheitherzonisamideortopiramate,
levetiracetam administration did not produce any decrements in
the performance on the neuropsychological tests used in this
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that levetiracetam treatment is not associated with cognitive im-
pairment in patients with seizure disorder.
29,30 T h el a c ko ft h e
effects of levetiracetam on cognitive functioning may result from
its comparatively selective actions on the brain, which most impor-
tantlymayinvolvebindingtothesynapticvesicleproteinS2A.59,60
In the present study, total OCDS scores for the topiramate
group became lower during the treatment period than for the pla-
cebo group. This is consistent with other findings that topiramate
administration may significantly reduce craving for alcohol as
measured by the OCDS in subjects with AD,
2,57 although this
wasnotfoundinastudyinwhichthisanticonvulsantwasreceived
f o ro n l y4w e e k s .
61 In contrast to topiramate, neither zonisamide
nor levetiracetam administration resulted in the significant reduc-
tionoftotalOCDSscorestobelowcontrollevels.Nevertheless,as
can be seen in Figure 3, mean values for total OCDS scores for
subjects in the zonisamide and levetiracetam groups seem to de-
cline below levels reached by the subjects in the placebo group.
Failure to detect significant differences in scores obtained for the
OCDSbetweenplaceboandeitherthezonisamideorthelevetirac-
etam group, therefore, might be related to the small size of these
groups in the present study.
The neuronal mechanisms through which topiramate and
zonisamide act to produce reductions in alcohol consumption in
AD remain to be fully elucidated. One possible mechanism that
these2 drugs may share tomodulate drinking behavior istocoun-
teract the enhanced excitability that may result from the selective
elevationinAMPA,N-methyl-D-aspartate, and/or kainate receptor
subunits seen in the hippocampus, the orbital frontal cortex, and
anterior cingulate cortex of individuals with AD.
62,63 Topiramate
maysuppressalcohol-inducedbrainexcitabilitythroughbothpos-
itive modulatory interactions with GABAA receptors containing
β1o rβ3 subunits
64 and antagonism of kainate receptors contain-
ing the GluK1 subunits.
65,66 Indeed, a recent report indicates that
sensitivity to topiramate-induced reductions in heavy drinking is
associated with the presence of a specific polymorphism of the
kainate receptor GluK1 subunit gene.
67 Excitatory glutamatergic
receptor activity may be reduced by zonisamide by the inhibition
of the stimulated release of glutamate
68 and by decreasing excit-
atory postsynaptic potentials through a postsynaptic mechanism
t h a tm a yi n v o l v ead i m i n u t i o ni nα-amino-3-hydroxy-5-methyl-
4-isoxazoleproprionicacid(AMPA)receptoractivity.
69Zonisamide
may also reduce brain excitability by enhancing the activity of
γ-aminobutyric acid (GABA) receptor systems by down-regulating
GABA transporter proteins.
70
The sample sizes used in the present study, although suffi-
cient for comparisons between active medication and placebo,
were too smallto allow for meaningful betweenactive medication
group comparisons of the proportion of subjects in these groups
who experienced a specific adverse event. Metabolic acidosis oc-
curred only in 1 patient in the topiramate group, and 19% of the
subjects in this group experienced paresthesias. In contrast, none
of the subjects in the zonisamide reported having symptoms of
paresthesia.Theseresultsareconsistentwithpreviousstudiesindi-
catingthatproblemsrelatedtotheinhibitionofcarbonicanhydrase
are more likely tooccur in individualstreated with topiramatethan
those who have received zonisamide.
8
The primary limitation of this study is the small number of
subjects included in each treatment group, which allows for only
efficacy comparisons between active drugs and placebo but is not
powered todetectefficacy differencesbetweenthe studydrugs.An-
other limitation of this study is that we did not enroll individuals
withthemostsevereformsofAUDs,namely,thosewithadvanced
liver disease, severe neurological impairment, and/or an inability
to maintain abstinence for even a short period, and consequently,
the value of using the drugs evaluated in the present study in se-
vere forms of AUDs needs further study.
The target maintenance doses of zonisamide and topiramate
were chosen based on previous findings.
2,19,31 In one previous
clinical trial, a higher 500-mg daily dose of zonisamide was cho-
sen for use. This dose also had efficacy in reducing alcohol con-
sumption in subjects with AD. Although a 300-mg maintenance
of topiramate was administered in the present study, other investi-
gators report efficacy with 75- and 200-mg daily doses of this
drug.56,57,67 It is possible that doses of zonisamide lower than
4 0 0m gd a i l ym a ya l s oh a v ee f f i c a c yi nt h et r e a t m e n to fA Di n
association with less cognitive impairment. At present, there has
been, however, no systematic comparison of different doses of
either zonisamide or topiramate on alcohol consumption or on
cognitive functioning in subjects with AD.
The results of this study provide further support that zoni-
samide has efficacy as a medication that can facilitate reduced
drinkinginindividualswithAD.Thisstudyhasprovidedaninitial
characterization of precise areas of cognitive functioning that may
be impaired by the administration of either topiramate or zoni-
samide in AD. Both agents seem to have the potential to produce
modest deficits incognitive functionintheareas of verbalfluency
and working memory. Evaluation of patientswith the A-B Neuro-
toxicityScaleindicatethatsubjectswithAUDSexperienceoverall
less impairment of cognition when treated with zonisamide than
with topiramate, with the latter drug having more pronounced ef-
fects on mental slowing. The findings of this study leave unre-
solved the question of whether zonisamide produces fewer adverse
effects related to the inhibition of carbonic anhydrase than does
topiramate. They do, however, point to the value of further inves-
tigation of the many compounds that have been synthesized that
are structurally related to these 2 drugs.
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